Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | YAP1 | P46937 | 1/20 | 0.37 |
| ▸ | TRHR | P34981 | 1/20 | 0.37 |
| ▸ | TRHDE | Q9UKU6 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7104066 | 1.00 | NPSR1 (0.38) | NPSR1MEN1KMT2AYAP1TRHR | |
| SCHEMBL7099521 | 0.94 | TRHDE (0.40) | NPSR1MEN1KMT2ATRHRTRHDE | |
| SCHEMBL7099517 | 0.94 | TRHDE (0.40) | NPSR1MEN1KMT2ATRHRTRHDE | |
| SCHEMBL7098746 | 0.90 | YAP1 (0.34) | YAP1TRHRTRHDENOS2KDM4E | |
| SCHEMBL7098748 | 0.90 | YAP1 (0.34) | YAP1TRHRTRHDENOS2KDM4E | |
| SCHEMBL7104341 | 0.86 | TRHR (0.37) | YAP1TRHRTRHDE | |
| SCHEMBL7104344 | 0.86 | TRHR (0.37) | YAP1TRHRTRHDE | |
| SCHEMBL7103875 | 0.85 | TRHR (0.41) | NPSR1MEN1KMT2ATRHRTRHDE | |
| SCHEMBL7103872 | 0.85 | TRHR (0.41) | NPSR1MEN1KMT2ATRHRTRHDE | |
| SCHEMBL7099084 | 0.85 | NPSR1 (0.43) | NPSR1MEN1KMT2ATRHRTRHDE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0991619-B1 | INHIBITORS OF ALPHA 4-BETA 1 MEDIATED CELL ADHESION | TANABE SEIYAKU CO (JP) | 2003-09-10 | — | — | EP | disclosed |
| US-20030130349-A1 | Inhibitors of alpha 4beta1 mediated cell adhesion | TANABE SEIYAKU CO., LTD. | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130349-A1 | Inhibitors of alpha 4beta1 mediated cell adhesion | VCAM1, ICAM1, ITGB1 | NPSR1 1330/4885MEN1 1388/4885KMT2A 4158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.